

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 November 2003 (13.11.2003)

(10) International Publication Number
WO 03/093266 A1

PCT

(51) International Patent Classification⁷: C07D 471/04, A61P 29/00 Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).

(21) International Application Number: PCT/US03/13042 (74) Agents: RUBIN, David et al.; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(22) International Filing Date: 25 April 2003 (25.04.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,

(25) Filing Language: English

AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data: 60/376,291 29 April 2002 (29.04.2002) US
(71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(72) Inventors; and

(75) Inventors/Applicants (for US only): JIAO, Richard [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). MORRIELLO, Gregori [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). YANG, Lihu [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). MOYES, Christopher [GB/GB];



(54) Title: TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

WO 03/093266 A1



(I)

(57) Abstract: The present invention is directed to compounds of the formula (I): (wherein R³ et R⁸ are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

TITLE OF THE INVENTION

TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE
MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

5 BACKGROUND OF THE INVENTION

The chemokines are a family of small (70-120 amino acids), proinflammatory cytokines, with potent chemotactic activities. Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract various cells, such as monocytes, macrophages, T cells, eosinophils, basophils and neutrophils 10 to sites of inflammation (reviewed in Schall, Cytokine, 3, 165-183 (1991) and Murphy, Rev. Immun., 12, 593-633 (1994)). These molecules were originally defined by four conserved cysteines and divided into two subfamilies based on the arrangement of the first cysteine pair. In the CXC-chemokine family, which includes IL-8, GRO α , NAP-2 and IP-10, these two cysteines are separated by a single amino 15 acid, while in the CC-chemokine family, which includes RANTES, MCP-1, MCP-2, MCP-3, MIP-1 α , MIP-1 β and eotaxin, these two residues are adjacent.

The chemokines are secreted by a wide variety of cell types and bind to specific G-protein coupled receptors (GPCRs) (reviewed in Horuk, Trends Pharm. Sci., 15, 159-165 (1994)) present on leukocytes and other cells. These chemokine 20 receptors form a sub-family of GPCRs, which, at present, consists of fifteen characterized members and a number of orphans. Unlike receptors for promiscuous chemoattractants such as C5a, fMLP, PAF, and LTB4, chemokine receptors are more selectively expressed on subsets of leukocytes. Thus, generation of specific chemokines provides a mechanism for recruitment of particular leukocyte subsets.

25 On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G protein, resulting in a rapid increase in intracellular calcium concentration. There are at least seven human chemokine receptors that bind or respond to β -chemokines with the following characteristic pattern: CCR-1 (or "CKR-1" or "CC-CKR-1") [MIP-1 α , MIP-1 β , 30 MCP-3, RANTES] (Ben-Barruch, et al., J. Biol. Chem., 270, 22123-22128 (1995); Beote, et al, Cell, 72, 415-425 (1993)); CCR-2A and CCR-2B (or "CKR-2A"/"CKR-2A" or "CC-CKR-2A"/"CC-CKR-2A") [MCP-1, MCP-2, MCP-3, MCP-4]; CCR-3 (or "CKR-3" or "CC-CKR-3") [Eotaxin, Eotaxin 2, RANTES, MCP-2, MCP-3] (Rollins, et al., Blood, 90, 908-928 (1997)); CCR-4 (or "CKR-4" or "CC-CKR-4") 35 [MIP-1 α , RANTES, MCP-1] (Rollins, et al., Blood, 90, 908-928 (1997)); CCR-5 (or

“CKR-5” or “CC-CKR-5”) [MIP-1 α , RANTES, MIP-1 β] (Sanson, et al., *Biochemistry*, 35, 3362-3367 (1996)); and the Duffy blood-group antigen [RANTES, MCP-1] (Chaudhun, et al., *J. Biol. Chem.*, 269, 7835-7838 (1994)). The β -chemokines include eotaxin, MIP (“macrophage inflammatory protein”), MCP (“monocyte chemoattractant protein”) and RANTES (“regulation-upon-activation, normal T expressed and secreted”) among other chemokines.

5 Chemokine receptors, such as CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, CXCR-4, have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including 10 asthma, rhinitis and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. Humans who are homozygous for the 32-basepair deletion in the CCR-5 gene appear to have less susceptibility to rheumatoid arthritis (Gomez, et al., *Arthritis & Rheumatism*, 42, 989-992 (1999)). A review of the role of eosinophils in allergic inflammation is provided by Kita, H., et al., *J. Exp. 15 Med.* 183, 2421-2426 (1996). A general review of the role of chemokines in allergic inflammation is provided by Lustger, A.D., *New England J. Med.*, 338(7), 426-445 (1998). A subset of chemokines are potent chemoattractants for monocytes and macrophages. The best characterized of these is MCP-1 (monocyte chemoattractant protein-1), whose primary receptor is CCR2. MCP-1 is produced in a variety of cell 20 types in response to inflammatory stimuli in various species, including rodents and humans, and stimulates chemotaxis in monocytes and a subset of lymphocytes. In particular, MCP-1 production correlates with monocyte and macrophage infiltration at inflammatory sites. Deletion of either MCP-1 or CCR2 by homologous recombination in mice results in marked attenuation of monocyte recruitment in 25 response to thioglycollate injection and *Listeria monocytogenes* infection (Lu et al., *J. Exp. Med.*, 187, 601-608 (1998); Kurihara et al. *J. Exp. Med.*, 186, 1757-1762 (1997); Boring et al. *J. Clin. Invest.*, 100, 2552-2561 (1997); Kuziel et al. *Proc. Natl. Acad. Sci.*, 94, 12053-12058 (1997)). Furthermore, these animals show reduced monocyte infiltration into granulomatous lesions induced by the injection of schistosomal or mycobacterial antigens (Boring et al. *J. Clin. Invest.*, 100, 2552-2561 (1997); Warmington et al. *Am J. Path.*, 154, 1407-1416 (1999)). These data suggest that MCP-1-induced CCR2 activation plays a major role in monocyte recruitment to inflammatory sites, and that antagonism of this activity will produce a sufficient suppression of the immune response to produce therapeutic benefits in 30

immunoinflammatory and autoimmune diseases. Accordingly, agents which modulate chemokine receptors such as the CCR-2 receptor would be useful in such disorders and diseases. In addition, the recruitment of monocytes to inflammatory lesions in the vascular wall is a major component of the pathogenesis of atherogenic plaque formation. MCP-1 is produced and secreted by endothelial cells and intimal smooth muscle cells after injury to the vascular wall in hypercholesterolemic conditions. Monocytes recruited to the site of injury infiltrate the vascular wall and differentiate to foam cells in response to the released MCP-1. Several groups have now demonstrated that aortic lesion size, macrophage content and necrosis are attenuated in MCP-1 $-\text{/}$ or CCR2 $-\text{/}$ mice backcrossed to APO-E $-\text{/}$, LDL-R $-\text{/}$ or Apo B transgenic mice maintained on high fat diets (Boring et al. *Nature*, 394, 894-897 (1998); Gosling et al. *J. Clin. Invest.*, 103, 773-778 (1999)). Thus, CCR2 antagonists may inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall.

15


SUMMARY OF THE INVENTION

The present invention is further directed to compounds which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, 20 allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

25

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of the formula I:



30

I

wherein:

R^3 is oxygen or is absent;

R^8 is selected from:

- 5 (a) hydrogen,
- (b) C_{1-3} alkyl, which is unsubstituted or substituted with 1-6
fluoro,
- (c) $-O-C_{1-3}$ alkyl,
- (d) fluoro, and
- (e) hydroxy;

10 and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

In an embodiment of the present invention R^3 is absent.

In an embodiment of the present invention R^3 is oxygen.

15

In the present invention it is preferred that R^8 is selected from:

20

- (a) hydrogen,
- (d) trifluoromethyl,
- (c) methyl,
- (d) methoxy,
- (e) ethoxy,
- (f) ethyl,
- (g) fluoro, and
- (h) hydroxy.

25

Representative compounds of the present invention include those presented in the Examples and pharmaceutically acceptable salts and individual diastereomers thereof.

The compounds of the instant invention have at least two asymmetric centers at the 1- and 3-positions of the cyclopentyl ring, one asymmetric center at the 4-position of the morpholine ring and optionally one asymmetric center at the 3-position of the morpholine ring. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or

partially purified compounds are included within the ambit of this invention. The independent syntheses of diastereomers and enantiomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by 5 the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.

As appreciated by those of skill in the art, C₁₋₃alkyl is defined to identify the group as having 1, 2 or 3 carbons in a linear or branched arrangement, 10 such that C₁₋₃alkyl specifically includes methyl, ethyl, n-propyl, and iso-propyl.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or 15 other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues 20 such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; 25 and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be 30 prepared from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or

acetonitrile are preferred. Suitable salts are found, e.g. in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418.

Specific compounds within the present invention include a compound which selected from the group consisting of: the title compounds of the Examples; and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

5 The subject compounds are useful in a method of modulating chemokine receptor activity in a patient in need of such modulation comprising the administration of an effective amount of the compound. The present invention is directed to the use of the foregoing compounds as modulators of chemokine receptor 10 activity. In particular, these compounds are useful as modulators of the chemokine receptors, in particular CCR-2.

The utility of the compounds in accordance with the present invention as modulators of chemokine receptor activity may be demonstrated by methodology known in the art, such as the assay for chemokine binding as disclosed by Van Riper, 15 et al., *J. Exp. Med.*, 177, 851-856 (1993) which may be readily adapted for measurement of CCR-2 binding.

Receptor affinity in a CCR-2 binding assay was determined by measuring inhibition of ^{125}I -MCP-1 to the endogenous CCR-2 receptor on various cell types including monocytes, THP-1 cells, or after heterologous expression of the 20 cloned receptor in eukaryotic cells. The cells were suspended in binding buffer (50 mM HEPES, pH 7.2, 5 mM MgCl₂, 1 mM CaCl₂, and 0.50% BSA) with and added to test compound or DMSO and ^{125}I -MCP-1 at room temperature for 1 h to allow binding. The cells were then collected on GFB filters, washed with 25 mM HEPES buffer containing 500 mM NaCl and cell bound ^{125}I -MCP-1 was quantified.

25 In a chemotaxis assay chemotaxis was performed using T cell depleted PBMC isolated from venous whole or leukophoresed blood and purified by Ficoll-Hypaque centrifugation followed by rosetting with neuraminidase-treated sheep erythrocytes. Once isolated, the cells were washed with HBSS containing 0.1 mg/ml BSA and suspended at 1×10^7 cells/ml. Cells were fluorescently labeled in the dark 30 with 2 μM Calcien-AM (Molecular Probes), for 30 min at 37° C. Labeled cells were washed twice and suspended at 5×10^6 cells/ml in RPMI 1640 with L-glutamine (without phenol red) containing 0.1 mg/ml BSA. MCP-1 (Peprotech) at 10 ng/ml diluted in same medium or medium alone were added to the bottom wells (27 μl). Monocytes (150,000 cells) were added to the topside of the filter (30 μl) following a 35 15 min preincubation with DMSO or with various concentrations of test compound.

An equal concentration of test compound or DMSO was added to the bottom well to prevent dilution by diffusion. Following a 60 min incubation at 37° C, 5 % CO₂, the filter was removed and the topside was washed with HBSS containing 0.1 mg/ml BSA to remove cells that had not migrated into the filter. Spontaneous migration
5 (chemokinesis) was determined in the absence of chemoattractant

In particular, the compounds of the following examples had activity in binding to the CCR-2 receptor in the aforementioned assays, generally with an IC₅₀ of less than about 1 μM. Such a result is indicative of the intrinsic activity of the compounds in use as modulators of chemokine receptor activity.

10 Mammalian chemokine receptors provide a target for interfering with or promoting eosinophil and/or lymphocyte function in a mammal, such as a human. Compounds which inhibit or promote chemokine receptor function, are particularly useful for modulating eosinophil and/or lymphocyte function for therapeutic purposes. Accordingly, compounds which inhibit or promote chemokine receptor function
15 would be useful in treating, preventing, ameliorating, controlling or reducing the risk of a wide variety of inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. For example, an instant compound which inhibits one or
20 more functions of a mammalian chemokine receptor (e.g., a human chemokine receptor) may be administered to inhibit (i.e., reduce or prevent) inflammation. As a result, one or more inflammatory processes, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, is inhibited.

25 In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian
30 species (e.g., chickens).

Diseases and conditions associated with inflammation and infection can be treated using the compounds of the present invention. In a preferred embodiment, the disease or condition is one in which the actions of lymphocytes are to be inhibited or promoted, in order to modulate the inflammatory response.

Diseases or conditions of humans or other species which can be treated with inhibitors of chemokine receptor function, include, but are not limited to: inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma, particularly bronchial asthma, allergic rhinitis,

5 hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic eosinophilic pneumonia), delayed-type hypersensitivity, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or

10 dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation),

15 including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis);

20 eosinophilic myositis, eosinophilic fasciitis; cancers with leukocyte infiltration of the skin or organs. Other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain hematologic malignancies, cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis.

25 Diseases or conditions of humans or other species which can be treated with modulators of chemokine receptor function, include, but are not limited to: immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS or other viral infections, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; immunosuppression due to congenital deficiency in receptor function or other causes; and infections diseases, such as parasitic diseases, including, but not limited to helminth infections, such as nematodes (round worms), (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, filariasis), trematodes (flukes) (Schistosomiasis, Clonorchiasis), cestodes (tape worms) (Echinococcosis, Taeniasis saginata, Cysticercosis), visceral worms,

30

35

visceral larva migraines (e.g., *Toxocara*), eosinophilic gastroenteritis (e.g., *Anisaki* sp., *Phocanema* sp.), and cutaneous larva migraines (*Ancylostoma braziliense*, *Ancylostoma caninum*). In addition, treatment of the aforementioned inflammatory, allergic and autoimmune diseases can also be contemplated for promoters of

5 chemokine receptor function if one contemplates the delivery of sufficient compound to cause the loss of receptor expression on cells through the induction of chemokine receptor internalization or delivery of compound in a manner that results in the misdirection of the migration of cells.

The compounds of the present invention are accordingly useful in

10 treating, preventing, ameliorating, controlling or reducing the risk of a wide variety of inflammatory and immunoregulatory disorders and diseases, allergic conditions, atopic conditions, as well as autoimmune pathologies. In a specific embodiment, the present invention is directed to the use of the subject compounds for treating, preventing, ameliorating, controlling or reducing the risk of autoimmune diseases,

15 such as rheumatoid arthritis or psoriatic arthritis.

In another aspect, the instant invention may be used to evaluate putative specific agonists or antagonists of chemokine receptors, including CCR-2. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the

20 activity of chemokine receptors. For example, the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for more potent compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other compounds to chemokine receptors, e.g., by competitive inhibition. The compounds of the instant invention are

25 also useful for the evaluation of putative specific modulators of the chemokine receptors, including CCR-2. As appreciated in the art, thorough evaluation of specific agonists and antagonists of the above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically resistant) compounds with high binding affinity for these receptors. Thus the compounds of this invention are

30 commercial products to be sold for these purposes.

The present invention is further directed to a method for the manufacture of a medicament for modulating chemokine receptor activity in humans and animals comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.

The present invention is further directed to the use of the present compounds in treating, preventing, ameliorating, controlling or reducing the risk of infection by a retrovirus, in particular, herpes virus or the human immunodeficiency virus (HIV) and the treatment of, and delaying of the onset of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.

In a preferred aspect of the present invention, a subject compound may be used in a method of inhibiting the binding of a chemokine to a chemokine receptor, such as CCR-2, of a target cell, which comprises contacting the target cell with an amount of the compound which is effective at inhibiting the binding of the chemokine to the chemokine receptor.

The subject treated in the methods above is a mammal, preferably a human being, male or female, in whom modulation of chemokine receptor activity is desired. "Modulation" as used herein is intended to encompass antagonism, agonism, partial antagonism, inverse agonism and/or partial agonism. In a preferred aspect of the present invention, modulation refers to antagonism of chemokine receptor activity. The term "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.

The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment. As used herein, the term "treatment" refers both to the treatment and to the prevention or prophylactic therapy of the aforementioned conditions.

Combined therapy to modulate chemokine receptor activity for thereby treating, preventing, ameliorating, controlling or reducing the risk of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, 5 and those pathologies noted above is illustrated by the combination of the compounds of this invention and other compounds which are known for such utilities.

For example, in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a 10 lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a 15 cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, embrel, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroid analgesic, sufentanil, sunlindac, tenidap, and the like. Similarly, the instant compounds may be administered with a pain reliever; a potentiator such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as 20 phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non-sedating antihistamine.

Likewise, compounds of the present invention may be used in 25 combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is 30 used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.

Examples of other active ingredients that may be combined with a compound of the present invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) VLA-4 antagonists such as those described in US 5,510,332, WO95/15973, WO96/01644, WO96/06108, 5 WO96/20216, WO96/22966, WO96/31206, WO96/40781, WO97/03094, WO97/02289, WO 98/42656, WO98/53814, WO98/53817, WO98/53818, WO98/54207, and WO98/58902; (b) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; 10 (c) immunosuppressants such as cyclosporin, tacrolimus, rapamycin and other FK-506 type immunosuppressants; (d) antihistamines (H1-histamine antagonists) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripeleamine, hydroxyzine, methdilazine, promethazine, trimethazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, desloratadine, cetirizine, fexofenadine, 15 descarboethoxyloratadine, and the like; (e) non-steroidal anti-asthmatics such as β 2-agonists (terbutaline, metaproterenol, fenoterol, isoetharine, albuterol, bitolterol, and pibuterol), theophylline, cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (zafirlukast, montelukast, pranlukast, irlukast, pobilukast, SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non- 20 steroidal antiinflammatory agents (NSAIDs) such as propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, 25 fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolafenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, 30 sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors; (h) inhibitors of phosphodiesterase type IV (PDE-IV); (i) other antagonists of the chemokine receptors, especially CCR-1, CCR-2, CCR-3, CXCR-3 and CCR-5; (j) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, 35 simvastatin and pravastatin, fluvastatin, atorvastatin, rosuvastatin, and other statins),

sequestrants (cholestyramine and colestipol), cholesterol absorption inhibitors (ezetimibe), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), and probucol; (k) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), α -glucosidase inhibitors (acarbose) and 5

glitazones (troglitazone and pioglitazone); (l) preparations of interferon beta (interferon beta-1 α , interferon beta-1 β); (m) other compounds such as 5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6-mercaptopurine, and cytotoxic cancer chemotherapeutic agents.

The weight ratio of the compound of the present invention to the 10 second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200.

15 Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used. In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, 20 concurrent to, or subsequent to the administration of other agent(s).

The compounds of the present invention may be administered by oral, 25 parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.

30 The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the 35 pharmaceutical compositions are prepared by uniformly and intimately bringing the

active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As 5 used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The pharmaceutical compositions containing the active ingredient may 10 be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting 15 of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium 20 phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over 25 a longer period. For example, a time delay material such as glycetyl monostearate or glycetyl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin 30 capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium 35

carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example

5 polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example

10 polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or

15 coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules

20 suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. The

25 pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and

30 esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or

sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.)

The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of these pathological conditions. In treating, preventing, ameliorating, controlling or reducing the risk of conditions which require chemokine receptor modulation an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, preferably 2.0 to 500, more preferably 3.0 to 200, particularly 1, 5, 10, 15, 20, 25, 30, 50, 75, 100, 125, 150, 175, 200, 250, 300, 400, 500, 600, 750, 800,

900, and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

Several methods for preparing the compounds of this invention are illustrated in the following Examples. The subject compounds may be prepared by modification of the procedures disclosed in the Examples as appropriate. Starting materials are made by known procedures or as illustrated. The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention. The following are representative procedures for the preparation of the compounds used in the following Examples or which can be substituted for the compounds used in the following Examples which may not be commercially available.

Concentration of solutions was generally carried out on a rotary evaporator under reduced pressure. Flash chromatography was carried out on silica gel (230-400 mesh). MPLC refers to medium pressure liquid chromatography and was carried out on a silica gel stationary phase unless otherwise noted. NMR spectra were obtained in CDCl_3 solution unless otherwise noted. Coupling constants (J) are in hertz (Hz). Abbreviations: diethyl ether (ether), triethylamine (TEA), N,N-diisopropylethylamine (DIEA) saturated aqueous (sat'd), room temperature (rt), hour(s) (h), minute(s) (min).


In some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.

Concentration of solutions was generally carried out on a rotary evaporator under reduced pressure. Flash chromatography was carried out on silica gel (230-400 mesh). NMR spectra were obtained in CDCl_3 solution unless otherwise noted. Coupling constants (J) are in hertz (Hz). Abbreviations: diethyl ether (ether),

triethylamine (TEA), N,N-diisopropylethylamine (DIEA) saturated aqueous (sat'd), room temperature (rt), hour(s) (h), minute(s) (min).

The following are representative Procedures for the preparation of the compounds used in the following Examples or which can be substituted for the 5 compounds used in the following Examples which may not be commercially available.


INTERMEDIATE 1



10

Intermediate 1 was prepared according to the procedure described in *J. Am. Chem. Soc.*, 1991, 113, 2079-2089.


INTERMEDIATE 2




15

To a solution of terahydro-4H-pyran-4-one (5.0 g, 50 mmol) and hexamethylphosphoramide (8.70 mL) in tetrahydrofuran (150 mL) was added slowly a solution of lithium diisopropylamide (31.25 mL, 2 M solution) in 125 mL of 20 tetrahydrofuran at -78 °C. The reaction mixture was stirred for 5 min and then ethyl iodide was added (16.0 mL, 200 mmol). The mixture was gradually warmed to 0 °C over 2 h. The reaction mixture was quenched with a saturated solution of NH4Cl and then extracted with ether (4 x 100 mL). The ether layer was washed with brine, dried (anhydrous magnesium sulfate), concentrated, and purified by flash column chromatography eluting with hexanes/ethyl acetate (4:1) to give Intermediate 2 (1.20 g, 20%).

INTERMEDIATE 3




Step A




To a mixture of 5,6-dihydro-4-methoxy-2H-pyran (10.0 g, 87.5 mmol) in methanol (200 mL) at 0 °C was added dropwise a solution of 3-chloroperoxy-benzoic acid (30.2 g, 175 mmol) in methanol (50 mL) via an addition funnel. The resulting solution was stirred for 5 h allowing it to warm to room temperature. The methanol was removed under reduced pressure affording a white solid. The material was dissolved in 500 mL of dichloromethane and cooled to 0 °C. To the mixture, while stirring vigorously, was added in portions an excess of solid calcium hydroxide (50-60 g). After stirring an additional 30 min, the mixture was filtered through a plug of celite and the filtrate was evaporated under reduced pressure to afford 11.62 g (82%) of the desired product as a clear oil. ¹H NMR (500 MHz, CDCl₃) δ 3.88-3.80 (m, 2H), 3.73-3.68 (m, 2H), 3.54-3.48 (m, 1H), 3.28 (s, 3H), 3.27 (s, 3H), 2.00-1.93 (m, 1H), 1.82-1.77 (m, 1H).

15 Step B



To a cooled (0 °C) solution of the product from Step A, Intermediate 3 (9.40 g, 58.0 mmol) in tetrahydrofuran (200 mL), under nitrogen, was slowly added NaH (2.32 g, 58.0 mmol) and the resulting slurry was stirred for 1 h at 0 °C. Iodomethane (7.22 mL, 116 mmol) was then added via syringe to the slurry and the resulting mixture was stirred overnight allowing it to warm to room temperature. The reaction was quenched with a saturated solution of ammonium chloride (200 mL) and the organic layer was then removed using a separatory funnel. The aqueous layer was extracted with ether (3 x 150 mL) and all the organics were combined, dried over anhydrous sodium sulfate, filtered, and evaporated *in vacuo*. Purification was accomplished by flash column using a stepwise gradient eluant of 10-60% ether/hexanes to afford 8.46 g (83%) of the desired product as a clear oil. ¹H NMR (500 MHz, CDCl₃) δ 3.98 (dd, J = 2.5, 12.4 Hz, 1H), 3.77 (ddd, J = 3.5, 7.1, 10.8 Hz, 1H), 3.57 (dd, J = 1.4, 12.4 Hz, 1H), 3.50 (dd, J = 2.5, 11.7 Hz, 1H), 3.46 (s, 3H), 3.25 (s, 3H), 3.22 (s, 3H), 3.22-3.20 (m, 1H), 1.96 (ddd, J = 4.7, 11.8, 16.5 Hz, 1H), 1.75 (br dd, J = 1.7, 14.2 Hz, 1H).

Step C




5 A solution of the product from Step B, Intermediate 3 (3.0 g, 17.04 mmol) in tetrahydrofuran/water (60 mL/10 mL) was treated with concentrated hydrochloric acid (6 mL) and the resulting solution was stirred at room temperature for 1 h. The mixture was concentrated *in vacuo* to remove the tetrahydrofuran and the aqueous layer then extracted with ether (6 x 50 mL). The organics were combined, dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to afford intermediate 24 (1.75 g, 79%) as a clear oil. ^1H NMR (500 MHz, CDCl_3) δ 4.23 (ddd, $J = 1.2, 11.4, 12.4$ Hz, 1H), 4.15-4.09 (m, 1H), 3.82 (dd, $J = 5.95, 8.7$ Hz, 1H), 3.74 (ddd, $J = 5.5, 8.5, 13.6$ Hz, 1H), 3.56 (dd, $J = 8.8, 11.3$ Hz, 1H), 3.50 (s, 3H), 2.61 (app dd, $J = 5.0, 8.9$ Hz, 2H).

10

15


INTERMEDIATE 4



20 This intermediate was prepared in an analogous fashion to that of Intermediate 3, except iodomethane was replaced with iodoethane. Purification by MPLC (gradient elution from 0-40% ethyl acetate/hexanes) afforded 683 mg (66%) of the final compound as a clear oil.

25


INTERMEDIATE 5



To a mixture of 5,6-dihydro-4-methoxy-2H-pyran (0.5 g, 4 mmol) in acetonitrile/water (15 mL, 1:1) at room temperature was added 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2.]octane bis(tetrafluoroborate) (1.5 g, 4.4 mmol,


SELECTFLUORTM) in one lot and the resulting reaction mixture was stirred at room temperature until completion. Solid NaCl was then added and the reaction mixture was then extracted with ether (4 x 50 mL). The ether layer was dried (anhydrous magnesium sulfate) and concentrated to yield 0.34 g (65%) of the title compound that 5 required no further purification. ¹H NMR (500 MHz, CDCl₃): δ 4.95 (m, 1H), 4.4-4.21 (m, 2H), 3.72-3.65 (m, 2H), 2.75 (m, 2H).

INTERMEDIATE 6



10


Step A



15 A mixture of tetrahydro-4*H*-pyran-4-one (10.0 g, 100 mmol) and pyrrolidine (11 g, 150 mmol) was stirred at room temperature for 1 h. The excess pyrrolidine was removed *in vacuo* and the residue was dried overnight under high vacuum. The enamine was obtained as a yellow liquid (14.7 g) which was used in the next step without further purification.

20

Step B




25 The enamine, prepared in Step A, Intermediate 6 (1.54 g, 10 mmol) and 4-N,N-dimethylpyridine (1.22 g) were treated with N,N-dimethylformamide (25 mL). The mixture was cooled to 0 °C and solid 5-(trifluoromethyl)dibenzothiophen-ium trifluoromethanesulfonate (4.0 g, 10 mmol) was added. The resulting mixture was stirred at 0 °C for 1 h, then quenched with 30 mL of concentrated aqueous HCl. The resulting mixture was stirred for 2 h and then extracted with ether (4 x 70 mL). The


combined ether layers were washed with water (50 mL) and brine (50 mL), dried over Na_2SO_4 , filtered, and evaporated. The residue was purified on silica gel (eluant: 10% ether/hexanes) to yield two components. The more polar component (200 mg) was the desired product. $^1\text{H-NMR}$ showed that it might exist in a semi-ketal form. ^1H NMR (500 MHz, CDCl_3) δ 4.43-3.38 (m, 5H), 3.24, 3.18 (ss, 3H) 2.52 (m, 1H), 1.82 (m, 1H). The less polar product (100 mg) was confirmed as alpha-alpha' di-trifluoromethyl tetrahydro-4H-pyran-4-one. ^1H NMR (500 MHz, CDCl_3) δ 4.59 (dd, 2H), 3.24, 3.80 (t, $J = 11.3$ Hz, 2H) 3.42 (m, 2H).

10

INTERMEDIATE 7



Step A



15


To a solution of 5-trifluoromethyl-2-pyridinal (51 g, 310 mmol) and sodium acetate (26.2g, 319 mmol) in glacial acetic acid (200 mL) was added bromine (16.7 mL, 325 mmol) and the resulting mixture was heated at 80 °C for 2.5 h. The reaction was allow to cool to room temperature and then was evaporated under reduced pressure.

20

The residue was neutralized with saturated NaHCO_3 solution and extracted with ethyl acetate (3 x 200 mL). The organics were combined, dried over MgSO_4 , filtered, and evaporated *in vacuo* to yield 74.45 g (98%) of the crude product. ^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, $J=2.6$ Hz, 1H), 7.89 (m, 1H).

25


Step B



Under nitrogen, the substituted pyridine described in Step A, Intermediate 7 (48.8g, 202 mmol) was added in small portions to a suspension of NaH (8.9 g, 220 mmol) in anhydrous tetrahydrofuran (500 mL). After complete addition of the intermediate, the reaction mixture was cooled to -78 °C and treated with *tert*-butyllithium (260 mL,


444 mmol) added dropwise via syringe. After stirring for 5 min, N,N-dimethylformamide (50 mL, 707 mmol) was added slowly to maintain the temperature below -50 °C. The resulting mixture was then stirred for 10 h allowing it to warm to room temperature. The mixture was quenched with 2 N HCl and then 5 diluted with ethyl acetate (1000 mL). The organic layer was separated, washed with brine, dried over MgSO₄, and evaporated *in vacuo*. The desired product was precipitated out of ethyl acetate and hexanes and filtered to yield a light brown solid (28.55 g, 74%). ¹H NMR (500 MHz, CD₃OD) δ 10.13 (s, 1H), 8.21 (s, 2H).

10 Step C



A mixture of the intermediate from Step B, Intermediate 7 (18 g, 95 mmol), sodium formate (7.1 g, 110 mmol), hydroxylamine hydrochloride (7.3 g, 110 mmol), and 15 formic acid (150 mL) was stirred at room temperature for 2 h and then heated to reflux overnight. The reaction mixture was cooled and allowed to stand at room temperature for 7 days. The reaction was poured into water and extracted with ethyl acetate (3 x). The combined organic layers were washed with water (2 x), saturated NaHCO₃ and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo* to yield the 20 desired product as a brown powder (17.84 g, 90%). ¹H NMR (400 MHz, CD₃OD) δ 8.37 (d, J=2.7 Hz, 1H), 8.19 (q, J=0.7 Hz, 0.3 Hz, 1H).

Step D



25 To a mixture of phosphorous oxychloride (13.4 mL, 144 mmol) and quinoline (8.7 mL, 73 mmol) was added the product from Step C, Intermediate 8, (24.6 g, 131 mmol) and the resulting mixture was heated to reflux for 3 h. The reaction was cooled to 100 °C before water (70 mL) was slowly added. The mixture was further cooled to room temperature and neutralized carefully with saturated NaHCO₃ 30 solution. The aqueous layer was extracted with ethyl acetate (3 x) and the organic layers were combined, dried over MgSO₄, filtered, and evaporated *in vacuo*. The crude product was purified by flash chromatography to afford (23.5 g, 87%) of the

desired compound. ^1H NMR (500 MHz, CDCl_3) δ 8.88 (d, $J=2.0$ Hz, 1H), 8.26 (d, $J=2.5$ Hz, 1H).


Step E



5

To a suspension of NaH (7.8 g, 200 mmol) in tetrahydrofuran (100 mL) under nitrogen was added dropwise a solution of *tert*-butyl methyl malonate (20 mL, 120 mmol) in anhydrous tetrahydrofuran (100 mL) via syringe. The reaction mixture was stirred for 0.5 h before a solution of the intermediate prepared in Step D, Intermediate 8 (20.1 g, 97.6 mmol) in tetrahydrofuran (200 mL) was added slowly via syringe. The reaction was stirred at room temperature overnight, then quenched with a saturated solution of NH_4Cl . The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 x). The combined organic layers were washed with water (3 x), dried over Na_2SO_4 , filtered, and evaporated *in vacuo*. Flash chromatography afforded 31.76 g (95%) of the pure desired product. ^1H NMR (500 MHz, CDCl_3) δ 9.03 (d, $J=1.5$ Hz, 1H), 8.25 (d, $J=2.0$ Hz, 1H), 5.25 (s, 1H), 3.86 (s, 3H), 1.52 (s, 9H).


Step F



20

A suspension of Raney Ni (1 g) and the product from Step E, Intermediate 7 (18.2 g, 52.9 mmol) in ethanol (130 mL) was placed on a Parr apparatus and hydrogenated at 40 psi H_2 overnight. The suspension was filtered through celite and the filtrate was evaporated *in vacuo* to afford 16.35 g (98%) of the crude product. ^1H NMR (500 MHz, CDCl_3) δ 8.83 (s, 1H), 7.89 (s, 1H), 7.82 (s, 1H), 4.83 (d, $J=16$ Hz, 1H), 4.72 (s, 1H), 4.49 (d, $J=16$ Hz, 1H), 1.45 (s, 9H).


Step G



To the mixture of the product from Step F, Intermediate 7 (16 g, 51 mmol) in dichloromethane (60 mL) was added TFA (30 mL) and the resulting mixture was stirred at room temperature for 0.5 h. The solution was evaporated under reduced pressure and the residue was dissolved in dichloromethane. The mixture was 5 neutralized by the slow addition of a solution of saturated sodium bicarbonate and the organic layer was removed. The aqueous layer was extracted with dichloromethane (4 x) and the combined organic layers were dried over Na_2SO_4 , filtered, and evaporated *in vacuo* to afford 10.42 g (95%) of the desired product. ^1H NMR (400 MHz, CDCl_3) δ 8.81 (s, 1H), 7.78 (s, 1H), 7.30 (s, 1H), 4.63 (s, 2H), 3.90 (s, 2H).


10

Step H



To a solution of the product from Step G, Intermediate 7 (18.0 g, 83.3 mmol) in tetrahydrofuran (50 mL) was added 1.0 M borane in tetrahydrofuran (417 mL, 420 mmol) and the resulting solution was stirred at room temperature overnight. The 15 solution was evaporated under reduced pressure and the residue was treated with 1% $\text{HCl}/\text{methanol}$ solution. The resulting mixture was heated at 50 °C overnight to breakdown the borane complex. Treatment with acidic methanol was repeated twice to insure that the borane complex was removed. A solution of this crude product 20 (83.3 mmol, assuming 100% conversion) and diisopropylethylamine (43 mL, 250 mmol) in dichloromethane was treated with di-*tert*-butyl dicarbonate (36.4 g, 167 mmol) and the resulting mixture was stirred at room temperature overnight. The 25 solution was washed with saturated sodium bicarbonate solution, water, and brine. The aqueous layers were combined and back-washed with dichloromethane (2 x). The combined organic layers were then dried over Na_2SO_4 , filtered, and evaporated to dryness. The crude product was purified by flash chromatography and MPLC to afford (11.89 g, 47%) as a yellow solid. ^1H NMR (500 MHz, CDCl_3) δ 8.69 (s, 1H), 7.66 (s, 1H), 4.67 (s, 2H), 3.79 (t, $J=6.0$ Hz, 2H), 3.08 (t, $J=5.5$ Hz, 2H), 1.51 (s, 9H).


30 Step I



The product described in Step H, Intermediate 8 (11.89 g) was treated with a solution of 4 N HCl in dioxane. The solution was stirred at room temperature for 2 h and then evaporated *in vacuo* to afford Intermediate 8 (10.85 g, 99%) as a yellow powder. LC-MS for $C_9H_{10}F_3N_2$ calculated 202.07, found $[M+H]^+$ 203.0.


5

INTERMEDIATE 8



Procedure A:


10 Step A



A mixture of (1*S*)-(+)-2-azabicyclo[2.2.1]hept-5-en-3-one (10.3 g, 94.4 mmol) in ethyl acetate (200 mL) and 10% Pd/C (0.5 g), was hydrogenated at room temperature. After 24 h the reaction mixture was filtered and evaporated leaving behind 10.4 g (100%) of the product that was taken in 250 mL methanol and HCl (12 M, 6 mL). The resultant mixture was stirred at room temperature, until the reaction was complete (72 h). Evaporation of methanol followed by drying under high vacuum, yielded title compound as an off white solid (16.0 g, 96%). 1H NMR (500 MHz, D_2O): δ 3.70 (s, 3H), 3.01 (m, 1H), 2.38 (m, 1H), 2.16-1.73 (m, 6H).

20


Step B



To a suspension of the intermediate from Step A (10.2 g, 56.8 mmol) in dry dichloromethane (200 mL) was added benzophenone imine (10.2 g, 56.8 mmol) at room temperature and the resultant mixture was stirred for 24 h. The reaction mixture was filtered and the filtrate was evaporated, to leave behind a yellow oil that was triturated with ether (100 mL), filtered and evaporated. This operation was repeated twice to ensure that the product was free of ammonium chloride impurities. The resultant oil was thoroughly dried under vacuum to yield the title compound (18.03 g,

>100%) and required no further purification. ^1H NMR (500 MHz, CDCl_3): δ 7.5-7.18 (m, 10H), 3.75 (m, 1H), 3.7 (s, 3H), 2.78 (m, 1H), 2.26-1.71 (m, 6H).

Step C




5

To a solution of lithium diisopropylamide (prepared from diisopropylamine (7.7 g, 76 mmol) and n-butyllithium (30.4 mL, 2.5 M in hexanes, 76 mmol) in tetrahydrofuran (120 mL) at -78°C was added the ester from step B (18.0 g, 58.6 mmol). The resultant burgundy colored solution was stirred for 20 min after which it was quenched with 2-iodopropane (14.9 gm, 88 mmol). The reaction mixture was gradually warmed over 3 h to 0°C and this temperature was maintained for an additional 3 h. Reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried (anhydrous magnesium sulfate) and concentrated to yield an oil. To the solution of the crude Schiff base (20.0 g) in tetrahydrofuran (100 mL) was added HCl (5.0 mL, 12 M). The resulting reaction mixture was allowed to stir at room temperature for 3 h. After the removal of all volatiles, the hydrochloride salt was taken up into dichloromethane (250 mL), saturated solution of sodium bicarbonate (250 mL) and di-tert-butyl dicarbonate (26.0 g, 1.4 Eq.) were added. The resultant mixture was vigorously stirred overnight at room temperature. The organic layer was separated and washed with water, brine, dried (anhydrous magnesium sulfate) and concentrated to yield an oil. Purification by flash column chromatography (eluent: hexanes/ethyl acetate 19 : 1) gave the desired product (4.91 g, 30%). ^1H NMR (500 MHz, CDCl_3): 4.79 (br, 1H), 4.01 (m, 1H), 3.71 (s, 3H), 2.18-1.60 (m, 6H), 1.44 (s, 9H), 0.87 (d, $J = 6.9$ Hz, 3H), 0.86 (d, $J = 6.9$ Hz, 3H).

25

Step D




30

To a solution of the ester from Step C (4.91 g, 17.2 mmol) in methanol (100 mL) was added a solution of LiOH (3.6 g, 85 mmol) in water (20 mL) and tetrahydrofuran (10 mL). The resultant mixture was heated at 80°C until the reaction was complete (18

h). The methanol was removed in *vacuo* and the crude product was taken up with water/ethyl acetate (200 mL, 1:4) and cooled to 0 °C. The acidity of the mixture was adjusted to pH 6. The ethyl acetate layer was separated, washed with water, brine, dried (anhydrous magnesium sulfate) and concentrated to yield an oil. Purification by 5 flash column chromatography (eluent: hexanes/ethyl acetate 1:1 + 2% AcOH) gave Intermediate 8 (3.9 g, 84%). ¹H NMR (500 MHz, CDCl₃): 11.36 (br, 1H), 6.49 (br, 1H), 4.83 (m, 1H), 3.71 (s, 3H), 2.30-1.55 (m, 6H), 1.46 (s, 9H), 0.94 (d, J = 6.9 Hz, 3H), 0.933 (d, J = 6.9 Hz, 3H).


10 Procedure B:

Step A:




15 Commercially available (1R,4S)-4-aminocyclopent-2-ene-1-carboxylic acid was converted to its methyl ester hydrochloride salt via classical procedures.

Step B:




20 To a suspension of amine from Step A (6.31 g, 35.5 mmol) in acetone (40 mL) and water (20 mL) was added solid NaHCO₃ (6.6 g, 78 mmol) in portions. After 5 min, a solution of di-*tert*-butyl dicarbonate (8.5 g, 39 mmol) in acetone (60 mL) was added and the reaction mixture was stirred at room temperature. After 3 h, acetone was removed *in vacuo* and the residue was partitioned between ether (500 mL) and 25 saturated aqueous NaHCO₃ solution (120 mL). The ether layer was further washed with aqueous NaHCO₃ solution (1 x 100 mL), brine (1x100 mL), dried over anhydrous Na₂SO₄, concentrated and purified by flash chromatography (15% ethyl acetate/hexanes) to afford the product (7.25 g, 85%).

30 Step C:



To a solution of lithium bis(trimethylsilyl)amide (10.4 g, 62.1 mmol) in tetrahydrofuran (100 mL) was added a solution of the intermediate from Step B (6.71 g, 27.8 mmol) in tetrahydrofuran (10 mL) over 10 min at -78 °C. The resulted 5 solution was stirred at -78 °C for 30 min before isopropyl iodide (3.3 mL, 33 mmol) was added in one portion. The reaction was allowed to warm up to -25 °C and this temperature was maintained overnight. The reaction was then quenched with an aqueous saturated NH₄Cl solution (250 mL). The organic layer was separated and the aqueous layer was further extracted with diethyl ether (3 x 100 mL). The combined 10 organic layers were then washed with brine (1 x 100 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by flash chromatography (5-10% ethyl acetate/hexanes) to give the product (5.66 g, 72%) as a clear oil (cis/trans = 4.3/1). ¹H NMR (500 MHz, CDCl₃) cis-isomer: δ 5.79 (s, 2H), 4.75 (m, 1H), 3.72 (s, 3H), 2.28- 2.20 (m, 2H), 2.0 (dd, J = 15, 4 Hz, 1H), 1.45 (s, 9H), 0.85 (d, J = 6.6 Hz, 3H), 0.81 15 (d, J = 7 Hz, 3H).


Step D:



To a solution of the product from step C (1.6 g, 5.7 mmol) in tetrahydrofuran (50 mL), 20 methanol (50 mL) and water (10 mL) was added LiOH monohydrate (400 mg) and the reaction was heated to reflux overnight until the TLC indicated that the reaction was complete. The organic solvents were removed *in vacuo* and the aqueous layer was washed with ether (1 x) and then acidified slowly with concentrated HCl until the pH reached 4. The resulting suspension was extracted with CH₂Cl₂ (3 x). The combined 25 organic layers were dried over anhydrous MgSO₄, filtered and concentrated to give the product as a mixture of two cis/trans isomers (1.5 g) as a foaming yellow solid. This solid was dissolved in ethyl acetate (2 mL) with heating and diluted with hexanes (50 mL) to give a clear solution. This solution was allowed to cool to room temperature slowly over 1 h and then maintained at -25 °C in a freezer overnight. The trans- 30 isomer was crystallized out along with some of the desired cis-isomer (500 mg total). The mother solution was collected and concentrated to give the title compound (1 g,

66%, cis-isomer only). ^1H NMR (500 MHz, CDCl_3) cis-isomer: δ 5.80 (m, 2H), 4.80 (m, 1H), 2.40-2.20 (m, 2H), 2.15-2.0 (m, 1H), 1.5 (m, 9H), 1.0-0.8 (m, 3H).


Step E:



5


To a solution of the product from Step D (1 g) in ethanol (30 mL) was added 10% Pd/C (100 mg) and the resulting mixture was agitated on a Parr apparatus at 50 lb pressure of H_2 overnight. The mixture was filtered through celite and concentrated in vacuo to afford the title compound (1 g, 99%). ^1H NMR (500 MHz, CDCl_3): 11.36 (br, 1H), 6.49 (br, 1H), 4.83 (m, 1H), 3.71 (s, 3H), 2.30-1.55 (m, 6H), 1.46 (s, 9H), 0.94 (d, J = 6.9 Hz, 3H), 0.933 (d, J = 6.9 Hz, 3H).

INTERMEDIATE 9



15


Step A



Intermediate 8 (4.6 g, 16 mmol) and Intermediate 11 (4.0 g, 14 mmol) were first dried by azeotropic distillation with toluene (3 x 50 mL) and placed under high 20 vacuum for 30 min. Under nitrogen, 4-dimethylaminopyridine (1.08 g, 8.60 mmol), anhydrous dichloromethane (40 mL), and diisopropylethylamine (7.0 mL, 40 mmol) were added sequentially. After Intermediate 8 was in solution, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (6.80 g, 14.3 mmol) was added, immediately followed by additional diisopropylethylamine (7.0 mL, 40 mmol). The 25 reaction mixture was stirred at room temperature overnight and then quenched with saturated NaHCO_3 . The aqueous layer was back washed with dichloromethane (3 x 50 mL) and the organic layers were combined, dried over Na_2SO_4 , filtered, and evaporated *in vacuo*. The crude product was purified by flash chromatography (stepwise gradient 0-60%, ethyl acetate/hexanes) to afford the product (4.80 g, 74%)

as a yellow foam. ^1H NMR (500 MHz, CDCl_3) δ 8.72 (s, 1H), 7.70 (s, 1H), 4.88 (br d, $J = 17.0$ Hz, 1H), 4.78 (d, $J = 17.6$ Hz, 1H), 4.04-3.84 (m, 2 H), 3.52 (br s, 1H), 3.12 (br t, $J = 5.6$ Hz, 1H), 2.32-2.06 (m, 3H), 1.98-1.70 (m, 4H), 1.64-1.54 (m, 1H), 1.44 (s, 9H), 0.92-0.82 (m, 6H). LC-MS for $\text{C}_{23}\text{H}_{32}\text{F}_3\text{N}_3\text{O}_3$ calculated 455.24, found 5 $[\text{M}+\text{H}]^+$ 456.2.


Step B




The from Step B, Intermediate 19 (1.2 g, 2.6 mmol) was dissolved with 4 N HCl in 10 dioxane (50 mL) and the resulting solution was stirred at room temperature for 1 h. The reaction was evaporated under vacuum to afford the product (904 mg, 97%) as a white powder. LC-MS calculated for $\text{C}_{18}\text{H}_{24}\text{F}_3\text{N}_3\text{O}$ is 355.20, found $[\text{M}+\text{H}]^+$ 356.2.

INTERMEDIATE 10

15




Step A



To a solution of the product described in Step A, Intermediate 19 (2.0 g, 4.4 mmol) in 20 dichloromethane (80 mL) was added 3-chloroperoxybenzoic acid (2.11 g, 8.83 mmol) and the resulting solution was stirred overnight at room temperature. The mixture was cooled to 0 °C and while stirring vigorously, solid calcium hydroxide was added in portions (about 6 g). The suspension was stirred for an additional 30 min, then 25 filtered through celite to remove all solids. The filtrate was evaporated *in vacuo* and the residue was purified by MPLC (gradient eluant 40-100% ethyl acetate/hexanes) to afford 1.32 g (64%) of the desired compound. ^1H NMR (500 MHz, CDCl_3) δ 8.46 (s, 1H), 7.28 (s, 1H), 4.88 (br d, $J = 17.2$ Hz, 1H), 4.78 (d, $J = 17.7$ Hz, 1H), 4.05-3.84


(m, 2 H), 3.12 (br s, 1H), 2.34-2.06 (m, 3H), 1.88-1.70 (m, 4H), 1.62-1.54 (m, 1H), 1.43 (s, 9H), 0.90-0.85 (m, 6H). LC-MS for $C_{23}H_{32}F_3N_3O_5$ calculated 471.20, found $[M+H]^+$ 472.2.

5 Step B




The product from Step B, Intermediate 20 (1.32 g, 2.82 mmol) was dissolved in 4 N HCl in dioxane (50 mL) and the resulting solution was stirred at room temperature for 1 h. The reaction was evaporated under vacuum to afford the product (1.10 g, 98%)
10 as a white powder. LC-MS for $C_{18}H_{24}F_3N_3O_2$ calculated 371.20, found $[M+H]^+$ 372.2.

EXAMPLE 1




15 A solution of Intermediate 9 (890 mg, 2.08 mmol), tetrahydro-4H-pyran-4-one (320 mg, 3.13 mmol), diisopropylethylamine (1.10 mL, 6.24 mmol) and crushed molecular sieves (4 Å, 500 mg) in dichloromethane (50 mL) was treated with sodium triacetoxyborohydride (2.20 g, 10.4 mmol) and stirred at room temperature overnight. The reaction was quenched with saturated sodium bicarbonate solution (50 mL) and diluted with an additional 25 mL of dichloromethane. The organic layer was separated and the aqueous layer was washed with dichloromethane (2 x 25 mL). The organics were combined, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by reverse phase HPLC to yield Example 1 (915 mg, 86.0%). LC-MS for $C_{23}H_{31}F_3N_3O_2$ calculated 439.24, found $[M+H]^+$ 440.2.

EXAMPLE 2



A solution of Intermediate 9 (304 mg, 0.712 mmol), Intermediate 1 (160 mg, 1.42 mmol), diisopropylethylamine (370 μ L, 2.14 mmol) and crushed molecular sieves (4 \AA , 150 mg) in dichloromethane (25 mL) was treated with sodium triacetoxyborohydride (755 mg, 3.56 mmol) and stirred at room temperature overnight. The reaction was quenched with saturated sodium bicarbonate solution (25 mL) and diluted with an additional 25 mL of dichloromethane. The organic layer was separated and the aqueous layer was washed with dichloromethane (2 x 20 mL). The organics were combined, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by preparative TLC (eluent: 0.5% NH₄OH/5% methanol/94.5% CH₂Cl₂) to yield 239 mg (74%) of the final product as a mixture of four diastereomers. Cis and trans racemate in reference to the pyran ring were resolved by HPLC equipped with a Preparative ChiralCel OD column (eluent: 5% ethanol/95% hexanes). Cis racemate was further resolved by using the Preparative ChiralPak AD column (eluent: 5% ethanol/95% hexanes). LC-MS for C₂₄H₃₅F₃N₃O₂ calculated 453.26, found [M+H]⁺ 454.3.

EXAMPLE 3




20

This product was prepared in an analogous fashion to that of Example 2, except Intermediate 1 was replaced with Intermediate 2. Purification by preparative TLC (eluent: 0.5% NH₄OH/5% methanol/94.5% CH₂Cl₂) afforded 203 mg (92%) as a mixture of four diastereomers. The single isomers were obtained by purification on an HPLC equipped with a Preparative ChiralCel OD column eluting with 5% ethanol/95% hexanes with a flow rate of 9 mL/min. LC-MS for C₂₅H₃₆F₃N₃O₂ calculated 467.28, found [M+H]⁺ 468.3 for all 4 isomer.

30


EXAMPLE 4



This product was prepared in an analogous fashion to Example 2, except Intermediate 1 was replaced with Intermediate 5. Purification by afforded 312 mg (88%) as a mixture of four diastereomers. LC-MS for $C_{30}H_{36}ClF_3N_3O_4$ calculated 593.23, found $[M+H]^+$ 594.3.

EXAMPLE 5

10




To the solution of the product described in Example 4 (286 mg, 0.482 mmol) in methanol (5 mL) was added a solution of 0.5 M sodium methoxide in methanol (1.2 mL, 0.58 mmol) and the resulting mixture was stirred at room temperature for 2 h.

15 After completion of reaction, the mixture was evaporated *in vacuo* and purified by preparative TLC (eluent: 1.0% NH₄OH/10% methanol/89% CH₂Cl₂) to yield Example 21 (201 mg, 91.6%) as a mixture of four diastereomers. LC-MS for $C_{23}H_{33}F_3N_3O_3$ calculated 455.24, found $[M+H]^+$ 456.25.

20

EXAMPLE 6




A solution of Intermediate 9 (500 mg, 1.17 mmol), Intermediate 3 (458 mg, 3.51 mmol), diisopropylethylamine (407 μ L, 2.34 mmol) and crushed molecular sieves (4

Å, 250 mg) in dichloromethane (25 mL) was treated with sodium triacetoxyborohydride (1.24 g, 5.85 mmol) and stirred at room temperature overnight. The reaction was quenched with saturated sodium bicarbonate solution (25 mL) and diluted with an additional 25 mL of dichloromethane. The organic layer was separated and the aqueous layer was washed with dichloromethane (2 x 20 mL). The organics were combined, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by preparative TLC (eluant: 1.0% NH₄OH/10% methanol/89% CH₂Cl₂) to yield 210 mg (86%) of the final product as a mixture of four diastereomers. The single isomers were obtained by using an HPLC equipped with a Preparative ChiralCel OD column eluting with 20% ethanol and 80% hexanes with a flow rate of 9 mL/min. LC-MS calculated for C₂₄H₃₄F₃N₃O₃ is 469.21, found [M+H]⁺ 470.2 for all 4 isomer. 3rd isomer off OD ChiralCel Column: ¹H NMR (500 MHz, CDCl₃) δ 8.72 (s, 1H), 7.69 (s, 1H), 4.87 (br d, J = 17.2 Hz, 1H), 4.75 (d, J = 17.4 Hz, 1H), 4.12 (dd, J = 3.1, 12.4 Hz, 1H), 3.99-3.86 (m, 3H), 3.47-3.39 (m, 1H), 3.41 (s, overlapped, 3H), 3.35-3.30 (m, 2H), 3.20-3.08 (m, 3H), 2.87-2.80 (m, 1H), 2.62-2.54 (m, 1H), 2.16-2.02 (m, 2H), 1.95 (br s, 1H), 1.88-1.81 (m, 1H), 1.78-1.57 (m, 6H), 1.41-1.32 (m, 1H), 0.96 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H). 4th isomer off OD ChiralCel Column: ¹H NMR (500 MHz, CDCl₃) δ 8.72 (s, 1H), 7.69 (s, 1H), 4.87 (br d, J = 17.6 Hz, 1H), 4.75 (d, J = 17.5 Hz, 1H), 4.10 (dd, J = 3.1, 12.3 Hz, 1H), 3.99-3.88 (m, 3H), 3.46-3.39 (m, 1H), 3.41 (s, overlapped, 3H), 3.35-3.30 (m, 2H), 3.17-3.09 (m, 3H), 2.86-2.80 (m, 1H), 2.64-2.55 (m, 1H), 2.16-2.10 (m, 1H), 2.05 (br s, 1H), 1.95-1.82 (m, 2H), 1.76-1.55 (m, 6H), 1.33-1.24 (m, 1H), 0.95 (d, J = 6.7 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H).

25

EXAMPLE 7




This product was prepared in an analogous fashion to that of Example 2, except
30 Intermediate 1 was replaced with Intermediate 4. The single isomers were obtained by using an HPLC equipped with a Preparative ChiralCel OD column eluting with

15% ethanol and 85% hexanes with a flow rate of 9 mL/min. LC-MS for $C_{25}H_{36}F_3N_3O_3$ calculated 483.23, found $[M+H]^+$ 484.2 for all four isomers.

EXAMPLE 8

5



This product was prepared in an analogous fashion to Example 2, except Intermediate 1 was replaced with Intermediate 5. LC-MS for $C_{24}H_{31}F_4N_3O_2$ calculated 457.23, 10 found $[M+H]^+$ 458.2 for all four isomers.

EXAMPLE 9

15

This product was prepared in an analogous fashion to Example 2, except Intermediate 1 was replaced with Intermediate 6. The single isomers were obtained by using an HPLC equipped with a Preparative ChiralCel OD column eluting with 5% ethanol and 95% hexanes with a flow rate of 9 mL/min. LC-MS for $C_{24}H_{31}F_6N_3O_2$ calculated 507.23, found $[M+H]^+$ 508.2 for all four isomers.


EXAMPLE 10

25

A solution of Intermediate 10 (641 mg, 1.60 mmol), tetrahydro-4*H*-pyran-4-one (220 mg, 2.24 mmol), diisopropylethylamine (279 μ L, 1.60 mmol) and crushed molecular

sieves (4 Å, 320 mg) in dichloromethane (20 mL) was treated with sodium triacetoxyborohydride (1.70 g, 8.00 mmol) and stirred at room temperature for no longer than 5 h. The reaction was quenched with saturated sodium bicarbonate solution (50 mL) and diluted with an additional 30 mL of dichloromethane. The 5 organic layer was separated and the aqueous layer was washed with dichloromethane (2 x 30 mL). The organics were combined, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by preparative TLC (eluant: 0.75% NH₄OH/7.5% methanol/91.75% CH₂Cl₂) to yield 626 mg (86%) of the final product. ¹H NMR (500 MHz, CDCl₃) δ 8.45, (s, 3H), 7.25 (s, 1H), 4.88 (br d, J = 17.4 Hz, 1H), 4.77 (d, J = 17.6 Hz, 1H), 4.00-3.85 (m, 4H), 3.41 (app t, J = 11.7 Hz, 2H), 3.22 (p, J = 6.8 Hz, 1H), 3.13-3.07 (m, 2H), 2.82-2.74 (m, 1H), 2.54-2.47 (m, 1H), 2.14 (dd, J = 6.8, 12.8 Hz, 1H), 2.07-2.00 (m, 1H), 1.94-1.86 (m, 2H), 1.84-1.77 (m, 3H), 1.65-1.57 (m, 2H), 1.46-1.26 (m, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H), LC-MS for C₂₃H₃₂F₃N₃O₃ calculated 455.24, found 10 15 [M+H]⁺ 456.2.


EXAMPLE 11



20 This product was prepared in an analogous fashion to Example 10, except tetrahydro-4H-pyran-4-one was replaced with Intermediate 1. The single isomers were obtained by using an HPLC equipped with a Preparative ChiralCel OD column eluting with 7% ethanol and 93% hexanes with a flow rate of 9 mL/min. LC-MS for C₂₄H₃₄F₃N₃O₃ calculated 469.24, found [M+H]⁺ 470.2, for all four isomers.

25


EXAMPLE 12



This product was prepared in an analogous fashion to Example 10, except tetrahydro-4*H*-pyran-4-one was replaced with Intermediate 2. The single isomers were obtained by using an HPLC equipped with a Preparative ChiralCel OD column eluting with 5% ethanol and 95% hexanes with a flow rate of 9 mL/min. LC-MS for C₂₅H₃₆F₃N₃O₃

5 calculated 483.24, found [M+H]⁺ 484.2, for all four isomers.

EXAMPLE 13




10 This product was prepared in an analogous fashion to Example 10, except tetrahydro-4*H*-pyran-4-one was replaced with Intermediate 3. The single isomers were obtained by using an HPLC equipped with a Preparative ChiralCel OD column eluting with 21% ethanol and 79% hexanes with a flow rate of 9 mL/min. LC-MS for C₂₄H₃₄F₃N₃O₄ calculated 485.25, found [M+H]⁺ 486.3, for all four isomers.

15

While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications with the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compounds selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

5 wherein:

R3 is oxygen or is absent;

R8 is selected from:

- (a) hydrogen,
- (b) C1-3alkyl, which is unsubstituted or substituted with 1-6
10 fluoro,
- (c) -O-C1-3alkyl,
- (d) fluoro, and
- (e) hydroxy;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

15

2. The compound of Claim 1 wherein R3 is absent.

3. The compound of Claim 1 wherein R3 is oxygen.

20




4. The compound of Claim 1 wherein

R8 is selected from:




- (a) hydrogen,
- (d) trifluoromethyl,
- (c) methyl,
- 25 (d) methoxy,
- (e) ethoxy,
- (f) ethyl,
- (g) fluoro, and
- (h) hydroxy.






30

5. A compound which is selected from the group consisting of:









5










5












5











5












5









and pharmaceutically acceptable salts and individual diastereomers thereof.

5 6. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

10 7. A method for modulation of chemokine receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

15 8. A method for the manufacture of a medicament for modulating chemokine receptor activity in humans and animals comprising combining the compound of Claim 1 with a pharmaceutical carrier or diluent.

19 9. A method for treating, ameliorating, controlling or reducing the risk of an inflammatory and immunoregulatory disorder or disease which comprises the administration to a patient of an effective amount of the compound of Claim 1.

20 10. A method for treating, ameliorating, controlling or reducing the risk of rheumatoid arthritis which comprises the administration to a patient of an effective amount of the compound of Claim 1.

INTERNATIONAL SEARCH REPORT

PCT/US 03/13042

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D471/04 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 02 070523 A (DIDIUK MARY THERESA ;GARIGIPATI RAVI SHANKER (US); LAU WAN FANG (U) 12 September 2002 (2002-09-12) page 1, line 6 -page 1, line 10; claims; examples --	1-10
A	US 2002/012664 A1 (LAROSA GREGORY J) 31 January 2002 (2002-01-31) column 1, paragraph '0005! claims; examples --	1-10 --

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 August 2003	22/08/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Schmid, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/13042

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	L. BORING, J. GOSLING, M. CLEARY, I.F. CHARO: "decreased lesion formation in CCR2 mice reveals a role for chemokines in the initiation of atherosclerosis" NATURE, vol. 394, 1998, pages 894-897, XP002250767 cited in the application the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/13042

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 7, 9 and 10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/13042

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
WO 02070523	A	12-09-2002	WO US	02070523 A1 2003008893 A1	12-09-2002 09-01-2003
US 2002012664	A1	31-01-2002	US AU CA EP JP WO US US US US US US US US US US	6312689 B1 5220899 A 2336250 A1 1098908 A2 2002521021 T 0005265 A2 6352832 B1 2002150576 A1 2002037285 A1 2002150570 A1 2002051781 A1 2002028436 A1 2002015700 A1 2002051782 A1	06-11-2001 14-02-2000 03-02-2000 16-05-2001 16-07-2002 03-02-2000 05-03-2002 17-10-2002 28-03-2002 17-10-2002 02-05-2002 07-03-2002 07-02-2002 02-05-2002